News
Researchers at the University of Texas at Austin have developed a noninvasive, wearable ultrasound patch that helps users reach REM sleep faster and maintain it longer. The NEUSLeeP device, which simultaneously monitors...
Read More
Georgia Tech researchers have developed a soft, wireless wearable that uses near-infrared spectroscopy to monitor glymphatic clearance dynamics in a natural home environment. This noninvasive technology offers a cost-eff...
Read More
New research from Flinders University suggests that relying on single-night sleep studies for obstructive sleep apnea may lead to misdiagnosis due to significant night-to-night variability. The study advocates for incorp...
Read More
A new case report demonstrates that combining the myTAP chairside titratable oral appliance with a mouth shield to enforce nasal breathing can significantly improve outcomes for patients with moderate-to-severe obstructi...
Read More
The latest version of the SOMNUM software analyzes polysomnography data to automatically detect and differentiate obstructive, central, and mixed sleep apnea.
Read More
New data suggest that targeting the underlying orexin deficiency can improve a broad spectrum of narcolepsy type 1 symptoms, from daytime cognition to nighttime sleep architecture.
Read More
The State of Sleep Medicine Report is compiled quarterly by the American Academy of Sleep Medicine as a members only resource. The report contains news highlights and announcements to help members identify current trends...
Read More
The FDA has granted Orphan Drug Designation to Tris Pharma’s TRN-257, an investigational once-nightly, low-sodium oxybate therapy for the treatment of idiopathic hypersomnia. The designation recognizes the potential for...
Read More
Phase 3 data on the orexin agonist oveporexton suggests that reducing microsleep frequency offers a more accurate reflection of real-world treatment response than traditional wakefulness tests alone.
Read More
The granted patent protects the proprietary oral combination therapy through at least 2040, as the company prepares to launch its Phase 2 dose optimization study.
Read More